Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 ...
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with ...
Candel Therapeutics Inc (NASDAQ:CADL) has reported updated clinical data showing extended survival outcomes from its ongoing ...
Candel Therapeutics (CADL) stock rises as the company updates results from an ongoing mid-stage trial for its lead candidate, CAN-2409 in lung cancer. Read more here.
Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.
EL PAÍS takes a journey through Ávila, Soria, Segovia and Valladolid in search of the places that captivated the brilliant ...
The FDA has previously granted fast track designation to aglatimagene plus valacyclovir in combination with ICI therapy for ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The ...
Neutral 2026 Cardano price outlook, key catalysts like Ouroboros Leios, CME futures, USDCx, and technical levels around $0.30 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results